Key Evidence #1
observationalPublic scholarly dataCitation signal: 189
The results demonstrate the superiority of a new sublingual form of GSH over the oral GSH form and NAC in terms of G SH supplementation.
Tier-BPublic-ready6/12/2026
NAC
Condition-specific health context in a specific context is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
Papers analyzed
20
Caution signal
Low
Representative score
59.2
Condition-specific health context in a specific contextExercise performance and recoveryNutrient status markers
Main benefit evidence
The representative ingredient tier is calculated from these target-level evidence groups.
Condition-specific evidence3 studiesTier-BCondition-specific health context in a specific contextFairly consistent positive signal in studiesResearch marker focusSupplement contextThis result was studied for Condition-specific health context in a narrower population or condition-specific context. It should not be generalized as an everyday supplement effect.Closer to a research marker than a directly felt benefit.Open metrics>
Condition-specific evidence
3 studiesTier-B
Condition-specific health context in a specific context
Fairly consistent positive signal in studiesResearch marker focusSupplement context
This result was studied for Condition-specific health context in a narrower population or condition-specific context. It should not be generalized as an everyday supplement effect.
Closer to a research marker than a directly felt benefit.
Open metrics
>Condition-specific health context
No direct rate reported. Read direction and evidence strength together.
Evidence score
52.0
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Exercise performance and recovery3 studiesTier-CExercise performance and recoveryFairly consistent positive signal in studiesFelt benefit focusSupplement contextPotential benefit studied in Exercise performance and recovery.Open metrics>
Exercise performance and recovery
3 studiesTier-C
Exercise performance and recovery
Fairly consistent positive signal in studiesFelt benefit focusSupplement context
Potential benefit studied in Exercise performance and recovery.
Open metrics
>Exercise performance and recovery
No direct rate reported. Read direction and evidence strength together.
Evidence score
45.7
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Nutrient status1 studiesTier-CNutrient status markersSome positive signal observedResearch marker focusPatient-group studyThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Nutrient status
1 studiesTier-C
Nutrient status markers
Some positive signal observedResearch marker focusPatient-group study
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit.
Closer to a research marker than a directly felt benefit.
Open metrics
>Nutrient status and deficiency markers
No direct rate reported. Read direction and evidence strength together.
Evidence score
44.0
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Blood pressure and vascular health1 studiesTier-CBlood pressure and vascular health markersSome positive signal observedResearch marker focusPatient-group studyThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Blood pressure and vascular health
1 studiesTier-C
Blood pressure and vascular health markers
Some positive signal observedResearch marker focusPatient-group study
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit.
Closer to a research marker than a directly felt benefit.
Open metrics
>Blood pressure and vascular markers
No direct rate reported. Read direction and evidence strength together.
Evidence score
42.1
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Stress and mood2 studiesTier-CStress Response and Sleep ChangesSome positive signal observedFelt benefit focusSupplement contextThese findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.Open metrics>
Stress and mood
2 studiesTier-C
Stress Response and Sleep Changes
Some positive signal observedFelt benefit focusSupplement context
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
Open metrics
>Stress and mood balance
No direct rate reported. Read direction and evidence strength together.
Evidence score
40.5
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Glucose and metabolic health2 studiesTier-CGlucose and metabolic health markersSome positive signal observedResearch marker focusPatient-group studyThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Glucose and metabolic health
2 studiesTier-C
Glucose and metabolic health markers
Some positive signal observedResearch marker focusPatient-group study
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit.
Closer to a research marker than a directly felt benefit.
Open metrics
>Glucose and metabolic markers
No direct rate reported. Read direction and evidence strength together.
Evidence score
30.2
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Recent research
Updated This Month10 new papers
10 new papers were added in this period. No new risk signal was identified.
What's new
10 new papers were added.No new risk signal was identified.
Most notable recent finding
This is the most meaningful new study in the latest update.
Why it mattersIt ranked highest among the newly collected papers for this ingredient in the latest update.
View paperStudy dosage range (reference only)
Lower dose
1
g/dayHigher dose
1
g/dayDosages used in research papers, shown as reference context.
Not personal dosing instructions, recommendations, or safety limits.
Key cautions to review
Standalone side-effect signals and combination cautions are listed separately.
Caution index
0.8
Caution band: Low
Caution signals
0
Side effects + combos + curated rules
Key precautions
No combination caution signal is clear enough to show right now. This does not guarantee safety.
Standalone side effects, combination cautions, and positive combos are separated below.
Side-effect and combination signals
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Evidence summaries
Paper IDs and full lists are private. Only study types and summaries are shown.
Key Evidence #2
observationalPublic scholarly dataCitation signal: 76
Evidence from the animal literature demonstrates a robust association for the prophylactic application of NAC and NACA post-TBI with improved neurofunctional outcomes and downregulation of inflammatory and oxidative stress markers at the tissue level.
Key Evidence #3
observationalPublic scholarly dataCitation signal: 45
This large scale clinical trial will investigate the efficacy of NAC as an adjunctive medication to clozapine and establish a cheap, safe and easy-to-use agent (NAC) as a ‘go to’ adjunct in patients that are only partly responsive to clazapine.
3 more summariesLimited representative sample by study type.>
Public scholarly dataCitation signal: 42
observationalThis trial suggests that NAC adds to the effect of citalopram in improving resistance/control to compulsions in OCD children and adolescents and is well tolerated.
Public scholarly dataCitation signal: 34
observational[Abstract]: Background The purpose of our study was to evaluate an inexpensive and available method to reduce mucous impactions in mechanically ventilated patients. Methods This randomized clinical trial was conducted on 40 mechanically ventilated patients age
Public scholarly dataCitation signal: 31
observationalThe preliminary findings suggest that tFUS could be potentially a promising neuromodulation tool for the direct and non-invasive management of the NAc and shed new light on the treatment for SUD and other brain diseases that involve reward processing.
NAC
arrow_backBack to listEvidence score: 59.2|Caution index: 0.8